Herborium Group, Inc. Enters the US Hispanic Market With Its Proprietary Acne Treatment AcnEase(R), a Novel Herbal, Clinically T
June 09 2009 - 8:00AM
Marketwired
Herborium Group, Inc. (PINKSHEETS: HBRM), a botanical therapeutics�
company that develops, licenses and markets novel botanical
ingredient based medicinal products, today announced that it has
entered the US Hispanic market with its breakthrough acne treatment
AcnEase�. The Hispanic market is the largest and most affluent
consumer ethnic market in the American marketing landscape.
Herborium has launched a multi-channel campaign to cover electronic
(Internet), as well as targeted wholesale and brand-building
channels for the Hispanic market, through its affiliation with
Hispanic Trending, Inc., a specialty marketing company.
"We are very excited about the potential for AcnEase�, our
novel, herbal acne treatment, in the Hispanic market," said Dr.
Agnes P. Olszewski, CEO of Herborium Group. "AcnEase is a most
suitable product for the Hispanic market, which has shown strong
interest and growth in consumer spending on beauty and grooming
products. In addition, AcnEase is the only over the counter acne
treatment that has no discoloration effect on olive toned, or
darker, complexion."
In clinical studies AcnEase� has demonstrated up to 95% efficacy
in diminishing acne, and improving skin condition, for both
Caucasian and non Caucasian skin types.
For more information about Herborium and AcnEase visit the
following links: www.herborium.com and www.acnease.com
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics� company, is
focused on developing, licensing, and marketing proprietary,
botanical based medicinal products to consumers and healthcare
professionals. The Company business model focuses on emerging
market opportunities spearheaded by the growth of a new market
sector located between high-cost, high-risk, ethical
pharmaceuticals and commoditized classic nutraceuticals
(supplements). The Company uses clinical validation and a proactive
regulatory strategy based on the FDA Guidance for the Industry:
"Botanical Drug Products (FDA Guidance 2004)" to establish and
maintain a differential advantage. Herborium harvests its
therapeutic candidates from Traditional Chinese Medicine and
utilizes Western regulatory, clinical and marketing strategies to
successfully introduce the products to Western markets. The company
has secured a pipeline of botanical ingredients based products in
the areas of dermatological needs, Prostate Health (BPH), Liver
Diseases, Women's Health and selected sexual disorders resulting
from cardiovascular disease, use of anti-depressants, surgical
procedures, and other problems. Herborium Group sells its products
in the United States, the United Kingdom, and continental Europe
through a network of distributors, specialty retailers, and
e-commerce.
Safe Harbor Statement: This release contains forward-looking
statements with respect to the results of operations and business
of Sunrise Consulting Group, Inc., which involves risks and
uncertainties. The Company's actual future results could materially
differ from those discussed. The Company intends that such
statements about the Company's future expectations, including
future revenues and earnings, and all other forward looking
statements be subject to the "Safe Harbors" provision of the
Private Securities Litigation Reform Act of 1995.
Contact: Herborium Group, Inc. Dr. Agnes Olszewski CEO 201 647
3757
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jul 2023 to Jul 2024